The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Apr. 09, 2019

Filed:

Nov. 27, 2017
Applicants:

Lisa Porter, Amherstburg, CA;

Bre-anne Fifield, Windsor, CA;

Dorota Lubanska, Windsor, CA;

Inventors:

Lisa Porter, Amherstburg, CA;

Bre-Anne Fifield, Windsor, CA;

Dorota Lubanska, Windsor, CA;

Assignee:

University of Windsor, Windsor, CA;

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A01K 67/027 (2006.01); A61K 49/00 (2006.01); C07K 14/005 (2006.01);
U.S. Cl.
CPC ...
A01K 67/0278 (2013.01); A01K 67/0275 (2013.01); A61K 49/0008 (2013.01); C07K 14/005 (2013.01); A01K 2207/15 (2013.01); A01K 2217/052 (2013.01); A01K 2217/072 (2013.01); A01K 2227/105 (2013.01); A01K 2267/0331 (2013.01); C12N 2740/12022 (2013.01);
Abstract

In one aspect, the invention provides a transgenic non-human animal model having germ cells and somatic cells containing an endogenous MMTV-SV40-Spy1A gene sequence introduced into said animal model or an ancestor of said animal model at an embryonic stage, wherein said gene sequence comprises a mouse mammary tumor virus gene (MMTV), a functionally disrupted SV40 gene (SV40) and a human Spy1A gene. In another aspect, the present invention provides a transgenic non-human animal model whose germ cells and somatic cells contain an endogenous Spy1A-pTRE-Tight gene sequence introduced into said animal model or an ancestor of said animal model at an embryonic stage. Preferably, the Spy1A-pTRE-Tight animal model expresses the Spy1A gene and develop cancer, preferably breast cancer, when administered with tetracycline, preferably doxycycline.


Find Patent Forward Citations

Loading…